亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Hybrid Capture DNA Sequencing Panel for Diagnosis and Detection of Lynch Syndrome and Other Cancer Types Associated with Mismatch Repair Deficiency

技術應用
Detection and diagnosis of Lynch Syndrome vs. somatic colorectal cancer.Detection and diagnostic subtyping of endometrial cancer.Detection and diagnosis of Constitutional Mismatch Repair Deficiency (CMMRD) in pediatric patients.Detection of mismatch repair (MMR) deficiency-associated microsatellite instability (MSI)
詳細技術說明
Integrative Panel to Detect Mismatch Repair Deficiency
*Abstract

Proper detection of the genetic and epigenetic alterations underlying cancer is critical for correct diagnosis and selection of treatment plans. In particular, determination of whether an MMR-associated cancer arose due to inherited mutations or somatic lesions in essential for guiding treatment plans of patients and, in the case of inherited cancer syndromes such as Lynch Syndrome, monitoring of family members of patients. Here, we introduce a novel method of using hybrid-capture DNA sequencing to detect point mutations, insertions and deletions, copy number alterations, structural rearrangements, promoter methylation, and microsatellite instability (MSI) to enable diagnosis of various MMR-associated and related cancers. This hybrid-capture approach utilizes a novel targeted probe panel enabling simultaneous readout of all of the aforementioned clinically-relevant sources of genome variation. In contrast to existing methods, this technology eliminates the need for sequential testing by multiple independent and complex tests (e.g., IHC), which are often not available in a single laboratory. This technology, therefore, has the potential to bring significant time and cost savings while providing best-in-class data quality for the detection of diagnosis of MMR-associated cancers.


Schematic representation of Lynch Syndrome vs. sporadic (somatic) colorectal cancer with regards to inactivation of selective MMR genes. Source: Sinicrope, Nature Reviews Clinical Oncology (2010).

*Principal Investigation
Dr. Trevor Pugh, Princess Margaret Cancer Centre, University Health Network.
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備